JP2016535780A5 - - Google Patents

Download PDF

Info

Publication number
JP2016535780A5
JP2016535780A5 JP2016552432A JP2016552432A JP2016535780A5 JP 2016535780 A5 JP2016535780 A5 JP 2016535780A5 JP 2016552432 A JP2016552432 A JP 2016552432A JP 2016552432 A JP2016552432 A JP 2016552432A JP 2016535780 A5 JP2016535780 A5 JP 2016535780A5
Authority
JP
Japan
Prior art keywords
therapeutic agent
patient
ferric citrate
kidney disease
chronic kidney
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2016552432A
Other languages
English (en)
Japanese (ja)
Other versions
JP2016535780A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2014/063643 external-priority patent/WO2015066593A1/en
Publication of JP2016535780A publication Critical patent/JP2016535780A/ja
Publication of JP2016535780A5 publication Critical patent/JP2016535780A5/ja
Pending legal-status Critical Current

Links

JP2016552432A 2013-11-04 2014-11-03 慢性腎臓病患者の心不全を軽減するためのクエン酸第二鉄 Pending JP2016535780A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201361899866P 2013-11-04 2013-11-04
US61/899,866 2013-11-04
PCT/US2014/063643 WO2015066593A1 (en) 2013-11-04 2014-11-03 Ferric citrate for reducing cardiac failure in chronic kidney disease patients

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2019140640A Division JP6828100B2 (ja) 2013-11-04 2019-07-31 慢性腎臓病患者の心不全を軽減するためのクエン酸第二鉄

Publications (2)

Publication Number Publication Date
JP2016535780A JP2016535780A (ja) 2016-11-17
JP2016535780A5 true JP2016535780A5 (enExample) 2017-12-14

Family

ID=53005244

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2016552432A Pending JP2016535780A (ja) 2013-11-04 2014-11-03 慢性腎臓病患者の心不全を軽減するためのクエン酸第二鉄
JP2019140640A Active JP6828100B2 (ja) 2013-11-04 2019-07-31 慢性腎臓病患者の心不全を軽減するためのクエン酸第二鉄
JP2021007091A Pending JP2021073230A (ja) 2013-11-04 2021-01-20 慢性腎臓病患者の心不全を軽減するためのクエン酸第二鉄

Family Applications After (2)

Application Number Title Priority Date Filing Date
JP2019140640A Active JP6828100B2 (ja) 2013-11-04 2019-07-31 慢性腎臓病患者の心不全を軽減するためのクエン酸第二鉄
JP2021007091A Pending JP2021073230A (ja) 2013-11-04 2021-01-20 慢性腎臓病患者の心不全を軽減するためのクエン酸第二鉄

Country Status (15)

Country Link
US (3) US20160256486A1 (enExample)
EP (2) EP3065734A4 (enExample)
JP (3) JP2016535780A (enExample)
KR (1) KR102392441B1 (enExample)
CN (1) CN105873583A (enExample)
AU (1) AU2014341975A1 (enExample)
BR (1) BR112016009901A8 (enExample)
CA (1) CA2928200A1 (enExample)
EA (1) EA201690926A1 (enExample)
HK (1) HK1223031A1 (enExample)
IL (1) IL245317A0 (enExample)
MX (1) MX2016005734A (enExample)
SG (1) SG11201603091QA (enExample)
TW (2) TWI744215B (enExample)
WO (1) WO2015066593A1 (enExample)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20120046753A (ko) 2009-07-21 2012-05-10 케릭스 바이오파마슈티컬스 인코포레이티드 구연산철 투여형태
KR102633597B1 (ko) 2013-06-05 2024-02-06 트리시다, 인크. 경구 투여를 위한 양성자-결합 중합체
EP3157516A4 (en) 2014-06-22 2017-12-13 Dexcel Pharma Technologies Ltd. Pharmaceutical compositions comprising ferric citrate and methods for the production thereof
IL322207A (en) 2014-12-10 2025-09-01 Tricida Inc Proton-binding polymers for oral administration
IL262660B2 (en) 2016-05-06 2024-04-01 Tricida Inc Compositions for and method of treating acid-base disorders
IL319146A (en) 2017-11-03 2025-04-01 Tricida Inc Compositions for and method of treating acid-base disorders
MX2021004640A (es) 2018-10-29 2021-05-28 Pharmacosmos Holding As Tratamiento de la deficiencia de hierro con carboximaltosa ferrica.
EA202191858A1 (ru) * 2019-06-12 2021-11-12 Фармакосмос Холдинг А/С Лечение дефицита железа у субъектов с риском нежелательных явлений со стороны сердечно-сосудистой системы и железо для лечения фибрилляции предсердий
EP4347022A1 (en) * 2021-05-27 2024-04-10 Keryx Biopharmaceuticals, Inc. Pediatric formulations of ferric citrate

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE351366B (enExample) * 1965-06-08 1972-11-27 Teikoku Hormone Mfg Co Ltd
US20050203169A1 (en) * 2001-08-06 2005-09-15 Moskowitz David W. Methods and compositions for treating diseases associated with excesses in ACE
TWI335218B (en) 2003-02-19 2011-01-01 Panion & Bf Biotech Inc Ferric organic compounds, uses thereof and methods of making same
US8093423B2 (en) 2003-02-19 2012-01-10 Globoasia, Llc Pharmaceutical-grade ferric organic compounds, uses thereof and method of making same
NZ566743A (en) * 2005-08-18 2010-07-30 Globoasia Llc Pharmaceutical-grade ferric organic compounds, uses thereof and methods of making same
KR20080094013A (ko) * 2006-01-30 2008-10-22 글로보아시아 엘엘씨 연조직의 석회화 역전, 예방, 지연 또는 안정화 방법
EP1978808B1 (en) 2006-01-30 2018-08-29 Panion & BF Biotech Inc. Ferric citrate for reversing, preventing, delaying or stabilizing soft tissue calcification
KR20120046753A (ko) * 2009-07-21 2012-05-10 케릭스 바이오파마슈티컬스 인코포레이티드 구연산철 투여형태
JP5827326B2 (ja) * 2010-07-07 2015-12-02 アーデリクス,インコーポレーテッド リン酸輸送を阻害する化合物及び方法
SG11201408521WA (en) * 2012-06-21 2015-01-29 Keryx Biopharmaceuticals Inc Use of ferric citrate in the treatment of chronic kidney disease patients

Similar Documents

Publication Publication Date Title
AR089862A1 (es) USO DE LAQUINIMOD PARA EL TRATAMIENTO DE PACIENTES CON ENFERMEDAD DE CROHN EN QUIENES FRACASO UNA TERAPIA ANTI-FACTOR DE NECROSIS TUMORAL a (ANTI-TNFa) DE PRIMERA LINEA
CN111989095A (zh) 预防或治疗肿瘤疗法副作用的方法
JP2016516751A5 (enExample)
JP2016510326A5 (enExample)
JP2019206562A5 (enExample)
HRP20201069T1 (hr) Primjena tasimelteona pod uvjetima natašte
JP2015522603A5 (enExample)
JP2014513121A5 (enExample)
JP2013523758A5 (enExample)
De Caridi et al. Effectiveness of prostaglandin E1 in patients with mixed arterial and venous ulcers of the lower limbs
JP2013538863A5 (enExample)
JP2017061488A5 (enExample)
MX2018011293A (es) Composicion farmaceutica de liberacion prolongada que comprende cisteamina o sal de la misma.
JP2017511307A5 (enExample)
Félix et al. Warfarin-induced gastric intramural hematoma
Send et al. Multiple causes for rhinolithiasis
WO2018051295A3 (en) Non-saponifiable compounds of natural lipids for use in the treatment of tumour pathologies
Pinero-Saavedra DRESS syndrome in an elderly patient: case report
Glezer et al. Decrease in heart rate in patients with coronary artery disease and chronic heart failure the purpose and means
JP2019529554A5 (enExample)
WO2018051294A3 (en) Non—saponifiable compounds of natural lipids for use in the treatment of cardiac pathologies
Protasov et al. The effectiveness of moxonidine in patients with uncomplicated hypertensive crisis
Park et al. Efficacy of inhaled iloprost in cor pulmonale and severe pulmonary hypertension associated with tuberculous destroyed lung
Torihashi Warfarin/heparin
Mittal et al. Post thoracotomy cardiorespiratory arrest: Perhaps avoidable?